讲座题目: Nanomedicine for RNAi-mediated synergistic therapy

主讲人: Dr. Young Jik Kwon, Associate professor with tenure at UC Irvine in the Pharmaceutical Sciences, Chemical Engineering and Materials Science, Biomedical Engineering and Molecular Biology and Biochemistry departments.

主持人:江文正 教授

开始时间: 2015-5-28 10:00

讲座地址: 闵行生科院534小会议室

主办单位: 天美娱乐 科技处

 

报告人简介：Dr. Young Jik Kwon is an associate professor with tenure at UC Irvine in the Pharmaceutical Sciences, Chemical Engineering and Materials Science, Biomedical Engineering and Molecular Biology and Biochemistry departments. Following his undergraduate education in Biological Engineering at Inha University, Dr. Kwon received his Ph.D in Chemical Engineering from the University of Southern California with a focus on retroviral gene delivery in 2013 and did post-doctoral training in department of chemistry at UC Berkeley on polymeric vaccine carriers. He started his academic career in Biomedical Engineering at Case Western Reserve University in 2005 and moved to UC Irvine in 2007. He currently oversees research at the BioTherapeutics Engineering Laboratory (BioTEL) at UC Irvine and his current projects mainly focus on gene therapy, drug delivery, cancer-targeted therapeutics, combined molecular imaging and therapy, and cancer vaccines. Dr. Kwon is a member of the NCI-designated Chao Family Comprehensive Cancer Center, the institute for Immunology, and the Center for Virus Research at UC Irvine. Dr. Kwon’s work was awarded the Medical Research Award from Gabrielle's Angel Foundation for Cancer Research in 2011, the Faculty Early Career Development Award (CAREER) from the National Science Foundation in 2010, and the Faculty Career Development Award from UC Irvine in 2008.

 

报告摘要🤟：The high complexity of diseases requires versatile and multi-modal approaches to achieving efficient and safe therapy. RNA interference (RNAi) is not only a powerful tool in basic research but also a promising therapeutic modality that can treat highly challenging diseases, including cancer, synergistically with other desirable therapies. A couple of examples of utilizing RNAi in addressing key challenges in the current cancer therapy will be presented in this talk. First example is to reverse drug-resistance in tamoxifen-treated breast cancer by silencing an enzyme that quenches tamoxifen-generated reactive oxygen species (ROS). Second example of such approach is to eradicate chronic myelogenous leukemia by restoring an apoptotic protein, Bim, and simultaneously silencing a pro-survival protein, Mcl-1, using novel viral/nonival hybrid vectors. The facilitated death of breast and leukemia cells were confirmed in vitro by various biochemical assays, and further validated in vivo using animal models. This talk will demonstrate the promising roles of RNAi as therapeutic potentiator in developing clinically desirable therapy.